NLS Pharmaceutics AG (NLSP) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    NLS Pharmaceutics AG

    NASDAQ: NLSP · Real-Time Price · USD
    1.92
    -0.07 (-3.52%)
    At close: Sep 05, 2025, 11:49 AM

    NLS Pharmaceutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a n/a
    Cost of Revenue
    		 11.41K 11.41K 10.05K
    Gross Profit
    		 -11.41K -11.41K -10.05K
    Operating Income
    		 -11.81M -15.48M -11.86M
    Interest Income
    		 n/a 100.87 68.13
    Pretax Income
    		 -12.17M -16.5M -11.95M
    Net Income
    		 -12.17M -16.5M -11.95M
    Selling & General & Admin
    		 5.9M 6.49M 5.93M
    Research & Development
    		 5.91M 8.98M 5.92M
    Other Expenses
    		 0.00 10.04K -17.32K
    Operating Expenses
    		 11.81M 15.47M 11.85M
    Interest Expense
    		 145.15K 100.87K 68.13K
    Selling & Marketing Expenses
    		 n/a 6.49M 5.93M
    Cost & Expenses
    		 11.81M 15.48M 11.86M
    Income Tax Expense
    		 n/a 2.00 n/a
    Shares Outstanding (Basic)
    		 38.18M 19.68M 14.75M
    Shares Outstanding (Diluted)
    		 38.18M 19.68M 14.75M
    EPS (Basic)
    		 -0.32 -0.84 -0.81
    EPS (Diluted)
    		 -0.32 -0.84 -0.81
    EBITDA
    		 -11.8M -15.47M -11.85M
    EBIT
    		 -11.81M -15.48M -11.88M
    Depreciation & Amortization
    		 11.41K 11.41K 10.05K

    Add to Watchlist